CCO Infectious Disease Podcast

Key Decisions in HIV Care: Renal and Hepatic Considerations in Older PWH

Episode Summary

In this on-demand recording of a live webinar, expert faculty review key renal and hepatic considerations, such as how to choose ART and what to monitor in older PWH.

Episode Notes

In this episode from the series “Key Decisions in HIV Care,” Jonathan Appelbaum, MD, FACP, AAHIVS, and Jens D. Lundgren, MD, DMSc, discuss important considerations for antiretroviral therapy (ART) use in older patients with renal and hepatic impairment.

• European AIDS Clinical Society guideline screening recommendations for kidney disease in people with HIV
• Antiretroviral dose adjustment recommendations based on estimated glomerular filtration rate
• Data on the use of full-dose lamivudine with renal impairment
• Data on the use of 2-drug nucleos(t)ide reverse-transcriptase inhibitor–sparing ART regimens, including GEMINI-1 and -2, TANGO, and SALSA for dolutegravir/lamivudine; SWORD-1 and -2 for dolutegravir/lamivudine; and ATLAS and FLAIR for long-acting cabotegravir plus rilpivirine
• US Department of Health and Human Services recommendations on the use of ART agents with hepatic impairment
• Recommendations from the American Gastroenterological Association on screening and diagnosis of nonalcoholic fatty liver disease (NAFLD)
• Prevalence of NAFLD, nonalcoholic steatohepatitis, and liver fibrosis in people with HIV
• Overlapping risk factors between HIV and NAFLD

Presenters:

Jonathan Appelbaum, MD, FACP, AAHIVS
Laurie L. Dozier Jr, MD, Education Director
Professor of Internal Medicine
Chair, Department of Clinical Sciences
Florida State University College of Medicine
Tallahassee, Florida 

Jens D. Lundgren, MD, DMSc
Professor
Rigshospital, University of Copenhagen
Director
Centre of Excellence for Health, Immunity and Infection (CHIP)
Rigshospital, University of Copenhagen
Copenhagen, Denmark 

Content based on an online CME program supported by educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; and ViiV Healthcare.

Follow along with the slides at:
https://bit.ly/3gAsu19

Link to full program:
https://bit.ly/3fOl0XX